Sanofi Logo

Together Against RSV Data Portal

Respiratory syncytial virus (RSV) is a leading cause of acute Lower Respiratory Tract Infections in young children and infants. RSV affects approximately 90% of infants by the age of two.1,2

In the UK, it is estimated that RSV accounts for approximately 30,000 infants being hospitalised every year.3 April 2022 to March 2023 RSV-related hospitalisations in infants and children under the age of five in England cost the NHS approximately £91 million.4

Using NHS Hospital Episode Statistics, data on hospital admissions has been broken down to show the impact infant RSV has on the NHS in your local area in England.

Use our tool to find out about the impact that infant RSV has in your area. Search by constituency or ICS region:


  1. Krilov L.r, et al. (2019) Respiratory Syncytial Virus Infection, Medscape. Accessed October 2023.
  2. Wennergren G, et al, (2001), Relationship between respiratory syncytial virus bronchiolitis and future obstructive airway diseases. European Respiratory Journal, 18:1044-1058. Accessed October 2023.
  3. Vaccine Knowledge Project (2020), Respiratory Syncytial Virus (RSV), available at: Accessed October 2023.
  4. Sanofi Data on File